products-page-bottom-left-box

Chloraf

Afrab-Chem Ltd
No. 22, Abimbola Street, Isolo Industrial Estate, Isolo, P.O. Box 1647, Lagos, Nigeria.
Email: info@afrabchem.com
Tel: 234-1-2700057
Fax: 234-1-4520328
Website: http://afrabchem.com/

Brand Name

Chloraf

Manufacturer

Afrab Chem Ltd, 22 Abimbola Street, Isolo Ind. Estate, Isolo, Lagos.

Therapeutic Class

Antibacterial, Others

Dosage Form, Composition & NAFDAC Registration Number (NRN)

Oral Suspenion (NRN:04-0543): Each 5 mL (teaspoonful) contains Chloramphenicol palmitate equivalent to 125 mg Chloramphenicol BP.

Pack size : Bottle of 60 mL and 100 mL Suspension.

chloraf suspension

Ear Drop (NRN:04-0325): Chloramphenicol BP 5%.

Pharmacology

Mode of action:

The mode of action is through the interference with or inhibition of protein synthesis in intact cells and in cell-free systems. In vitro Chloramphenicol exerts mainly a bacteriostatic effect on a wide range of gram negative and gram-positive bacteria and is active in vitro against rickettsias, the lymphogranuloma psittacosis group and Vibrio cholerae. It is particularly active against Salmonella typhi and Hemophilus influenzae.

Potent, potentially toxic broad-spectrum antibiotic which should be reserved for life threatening infection particularly those caused by Haemophilus influenzae and Salmonella typhi.

Indications

Typhoid and paratyphoid fevers caused by S.typhi and S.paratyphi and other Salmonella infections; meningitis caused by Haemophilus influenzae; Rickettsial infections and epidemic typhus, chronic infection of urinary tract caused by Proteus vulgaris which does not respond to treatment with other antibiotics.

Contra-indications

Hypersensitivity to Chloramphenicol, infections which can be treated with less toxic antibiotics, cerebral fluid infections, bone marrow disease such as leucopenia, thrombocytopenia, pregnancy and breast feeding.

Avoid use in neonates

Precautions/Warnings

Avoid long term treatment (not more than 10 days) and in hepatic renal impairment, regular blood cell count should be performed.

Advice to Patients:

Do not initiate or discontinue this medication without medical consultation or prescription. Do not use any medicine after "Expiry date" on the pack.

Interactions

Avoid concomitant use with anticoagulants, antidiabetic agents, anti-epileptics; discontinue the treatment if serum iron level is high. Systemic half-life is enhanced by drugs that inhibit liver oxidase enzymes such as rifampicin, paracetamol, phenobarbitone, phenytoin. This is important in cases of poor liver dysfunction, mild toxicity to chloramphenicol and low blood count.

Adverse Effects

Agranulocytosis, aplastic anaemia, thrombocytopenic purpura and bone marrow suppression may occur in long term therapy.

Other side effects include renal toxicity, optic neuritis, jaundice, dryness of the mouth, nausea, vomiting, diarrhoea, skin rashes; increased growth of Candida albicans or other fungi on the mucous membrane may occur causing stomatitis, sore tongue and rectal or vaginal irritations.

Haemolytic anaemia in some patients with a genetic deficiency of glucose-6-phosphate dehydrogenase Athens the colour of the skin; irregular respiration, perspiration, progressive pallid cyanosis, circulatory collapse and eventually death.

Prolonged administration may induce bleeding, either bone marrow depression or by reduction of intestinal flora which leads to inhibition of vitamin K synthesis hence high prothrombin time.

Dosage & Administration

25-50 mg/kg body weight daily in divided doses every six hours. Maximum daily dose should not exceed 2 g.

Plasma concentration monitoring required in neonates and preferably also in those under 4 years of age; recommended plasma concentration 15-25 mg/litre.

Storage/Handling Recommendations

Store in a cool dry place between 15 - 25ºC.

Keep away from the reach of children.

Review Date

2017-09-18 12:00:35